News

Kiadis Pharma receives IND approval from FDA to start pivotal clinical trial with ATIR™ 08-07-2010
Biopharmaceutical Company Kiadis Pharma announced today that it has received approval for its Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) to start the pivotal clinical study for its product ATIR™ in the United States. Kiadis Pharma is currently... read more 

Kiadis Pharma Provides ATIR™ Update: Two Year Follow-Up Data Show No Cases of Transplant Related Mortality - FDA grants ATIR™ Orphan Drug Status as a Medicinal Cell Based Therapy to Reduce Transplant Related Mortality 28-04-2010
Kiadis Pharma today provided an update on its cell therapy product ATIR™ developed for mismatched bone marrow transplants. ATIR™ continues to show excellent clinical results in patients who received a mismatched bone marrow transplantation from a family member donor. The two year follow up data... read more 

About us

Kiadis Pharma in brief

Kiadis Pharma is a biopharmaceutical company focused on complications and limitations of hematopoietic stem cell transplants (HSCT) in blood cancer patients. The company has three blood cancer products in clinical development that offer novel treatment options for terminally ill cancer patients addressing high-unmet medical needs. Kiadis Pharma is headquartered in Amsterdam, The Netherlands.

 

Kiadis Pharma has recently begun a registration study for ATIR™, the Company’s lead clinical program. Patients are being enrolled at clinical sites in various European countries as well as in Canada and the United States. For more information about enrolment in a clinical study of ATIR™, see www.clinicaltrials.gov

Kiadis Pharma

Entrada 231-234
1096 EG  Amsterdam
The Netherlands


T +31 (0)20 314 02 50
F +31 (0)20 314 02 51